Photobiomodulation in the Prevention and Management of Oral Mucositis in Children

Inclusion Criteria

• •Age 4 to 17 years
• •Histopathologic diagnosis of malignant neoplasm: leukemia, lymphoma, or solid tumor of the head and neck.
• •Within days 1-3 of the start of any chemotherapy cycle; for leukemia patients, in consolidation phase as defined by protocol.
• •No signs of oral mucositis at enrollment.
• •Availability and willingness to attend scheduled photobiomodulation (PBM) application sessions.
• •Parent/legal guardian signed informed consent and child assent when applicable (≥ 8 years).
• •No documented primary immunodeficiency.
• •No severe concomitant systemic infection or medical condition that, in the investigator's judgment, contraindicates participation.
• •No PBM treatment within 14 days prior to enrollment.
• •No history of adverse reactions to light therapies or known photosensitivity.
• •No history of seizure disorder or diagnosis of epilepsy.
• •Age 4 to 17 years
• •Histopathologic diagnosis of malignant neoplasm: leukemia, lymphoma, or solid tumor of the head and neck.
• •Currently receiving chemotherapy (any cycle of the regimen).
• •Presence of oral mucositis of any grade during chemotherapy, identified within the first 3 days from onset of the mucositis episode.
• •Parent/legal guardian signed informed consent and child assent when applicable (≥ 8 years).
• •No documented primary immunodeficiency.
• •No severe concomitant systemic infection or medical condition that, in the investigator's judgment, contraindicates participation.
• •No photobiomodulation (PBM) treatment within 14 days prior to enrollment.
• •No history of adverse reactions to light therapies or known photosensitivity.
• •No history of seizure disorder or diagnosis of epilepsy.